Zentalis Pharmaceuticals, Inc.
General ticker "ZNTL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $132.4M (TTM average)
Zentalis Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 9.4%.
Estimated limits based on current volatility of 2.7%: low 1.33$, high 1.40$
Factors to consider:
- Total employees count: 168 (+7.7%) as of 2023
- Top business risk factors: Limited operating history and no commercial products, Labor/talent shortage/retention, Regulatory and compliance, Cybersecurity threats, Strategic risks and growth management
- Current price 20.1% below estimated low
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.75$, 5.38$]
- 2025-12-31 to 2026-12-31 estimated range: [2.19$, 6.24$]
Financial Metrics affecting the ZNTL estimates:
- Positive: with PPE of -1.3 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -78.81 <= 0.33
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Shareholder equity ratio, % of 78.35 > 63.39
- Positive: Investing cash flow per share per price, % of 81.44 > -0.66
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ZNTL quotes
Long-term ZNTL plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $67.42MM |
| Operating Expenses | $227.29MM | $299.51MM | $258.62MM |
| Operating Income | $-227.29MM | $-299.51MM | $-191.19MM |
| Non-Operating Income | $-10.29MM | $6.60MM | $25.50MM |
| Interest Expense | $2.58MM | $0.00MM | $0.00MM |
| R&D Expense | $172.73MM | $235.16MM | $167.77MM |
| Income(Loss) | $-237.58MM | $-292.91MM | $-165.69MM |
| Taxes | $-0.47MM | $-0.60MM | $0.18MM |
| Profit(Loss)* | $-236.81MM | $-292.19MM | $-165.84MM |
| Stockholders Equity | $433.80MM | $437.28MM | $337.19MM |
| Assets | $539.31MM | $551.69MM | $430.34MM |
| Operating Cash Flow | $-163.75MM | $-207.82MM | $-170.86MM |
| Capital expenditure | $2.55MM | $0.58MM | $0.22MM |
| Investing Cash Flow | $-114.18MM | $-44.46MM | $176.56MM |
| Financing Cash Flow | $261.04MM | $237.30MM | $0.11MM |
| Earnings Per Share** | $-4.48 | $-4.47 | $-2.33 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.